logo

For the Inventor, By the Inventor

Albuquerque, NM, United States of America

John D Maynard

This inventor holds 19 USPTO granted patents and 8 published patent applications, primarily in Noninvasive Spectroscopy. Top assignees: Trutouch Technologies, Inc., Veralight, Inc., Inlight Solutions, Inc.. Active years: 2003-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John D Maynard. Retrieved from https://idiyas.com/inventor/john-d-maynard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 

% Patents Active = 31.6

Average Co-Inventor Count = 3.9

ph-index = 16

Forward Citations = 1,889(Granted Patents)


Company Filing History:

goldMedal7 out of 11 
 
Trutouch Technologies, Inc.
 patents
silverMedal7 out of 8 
 
Veralight, Inc.
 patents
bronzeMedal4 out of 22 
 
Inlight Solutions, Inc.
 patents
4. 1 out of 13 
 
Rio Grande Medical Technologies, Inc.
 patents

Years Active: 2003-2014

Loading Chart...
Areas of Expertise:
Noninvasive Detection
Tissue Fluorescence
Raman Spectroscopy
Glycation End-Product
Alcohol Concentration
Spectrometer Stability
Optical Sampling
Glucose Measurement
Multivariate Calibration
Hemoglobin Correction
19 patents (USPTO):Explore Patents
1. 8676283 - Method and apparatus to compensate for melanin and hemoglobin variation in determination of a measure of a glycation end-product or disease state using tissue fluorescence (2014-03-18),
2. 8581697 - Apparatuses for noninvasive determination of in vivo alcohol concentration using raman spectroscopy (2013-11-12),
3. 8515506 - Methods for noninvasive determination of in vivo alcohol concentration using Raman spectroscopy (2013-08-20),
4. 8238993 - Determination of a measure of a glycation end-product or disease state using tissue fluorescence lifetime (2012-08-07),
5. 8174394 - System for noninvasive determination of analytes in tissue (2012-05-08),
6. 8140147 - Determination of a measure of a glycation end-product or disease state using a flexible probe to determine tissue fluorescence of various sites (2012-03-20),
7. 8131332 - Determination of a measure of a glycation end-product or disease state using tissue fluorescence of various sites (2012-03-06),
8. 8121671 - Determination of a measure of a glycation end-product or disease state using tissue fluorescence preferentially from the dermis (2012-02-21),
9. 8078243 - Determination of a measure of a glycation end-product or disease state using tissue fluorescence (2011-12-13),
10. 7889349 - Method and apparatus for improvement of spectrometer stability, and multivariate calibration transfer (2011-02-15),
11. 7616123 - Apparatus and method for noninvasively monitoring for the presence of alcohol or substances of abuse in controlled environments (2009-11-10),
12. 7446878 - Method and apparatus for improvement of spectrometer stability, and multivariate calibration transfer (2008-11-04),
13. 7403804 - Noninvasive determination of alcohol in tissue (2008-07-22),
14. 7139598 - Determination of a measure of a glycation end-product or disease state using tissue fluorescence (2006-11-21),
15. 6944487 - Determination of pH including hemoglobin correction (2005-09-13),

Title: Innovations of John D. Maynard: Pioneering Advances in Tissue Analysis

Introduction

John D. Maynard, based in Albuquerque, NM, is an esteemed inventor with a remarkable portfolio that includes 19 patents. His groundbreaking work focuses on non-invasive methods for analyzing tissue states, with particular applications in medical diagnostics.

Latest Patents

Among his notable inventions is a patented method and apparatus designed to compensate for melanin and hemoglobin variation in the determination of glycation end-products or disease states using tissue fluorescence. This innovative method involves illuminating a portion of the skin with excitation light. The emitted light due to fluorescence is then detected, allowing for the assessment of the tissue state while mitigating the effects of time-varying signals like those caused by hemoglobin.

Additionally, Maynard has developed apparatuses for the non-invasive determination of alcohol concentration in blood or tissue using Raman spectroscopy. This method involves illuminating tissue and analyzing the Raman scattered light to derive alcohol concentration. The technology prides itself on being highly optimized, providing consistent measurement while incorporating correction techniques for accuracy, making it a significant advancement in the medical field.

Career Highlights

Throughout his career, John D. Maynard has made significant contributions in the innovation landscape, having worked with esteemed companies such as Veralight, Inc. and TruTouch Technologies, Inc. His work has played a critical role in enhancing non-invasive medical diagnostic techniques.

Collaborations

Maynard has collaborated with notable colleagues, including Robert D. Johnson and Trent D. Ridder. Together, they have contributed to advancements in imaging and diagnostic technologies, combining their expertise to push the boundaries of non-invasive diagnostics.

Conclusion

John D. Maynard's contributions to the field of tissue analysis through his innovative patents have paved the way for significant advancements in medical diagnostics. His work exemplifies the importance of innovation in improving health outcomes and represents a significant step towards non-invasive diagnostic techniques.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…